| term overlap_mean setsize_mean score_mean pval_mean overlap_std setsize_std score_std pval_std |
| 15q112 copy number variation syndrome 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 15q133 copy number variation syndrome 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 16p112 distal deletion syndrome 0.0 23.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 16p112 proximal deletion syndrome 0.0 62.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 1q211 copy number variation syndrome 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 22q112 copy number variation syndrome 1.0 86.0 2.415606242496999 0.3459346535427879 0.0 0.0 0.0 0.0 |
| 3q29 copy number variation syndrome 0.0 45.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 4hydroxytamoxifen dexamethasone and retinoic acids regulation of p27 expression 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 7oxoc and 7betahc pathways 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| 7q1123 copy number variation syndrome 0.0 90.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ace inhibitor pathway 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Acetylcholine synthesis 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Acquired partial lipodystrophy barraquersimons syndrome 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Activation of nlrp3 inflammasome by sarscov2 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Acute viral myocarditis 0.0 57.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Adipogenesis 0.0 73.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Aerobic glycolysis 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Aflatoxin b1 metabolism 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Agerage pathway 1.0 52.0 4.039615846338536 0.2260688267312995 0.0 0.0 0.0 0.0 |
| Airway smooth muscle cell contraction 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Alanine and aspartate metabolism 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Allograft rejection 0.0 30.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Alpha 6 beta 4 signaling pathway 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Altered glycosylation of muc1 in tumor microenvironment 1.0 6.0 10.0 0.0290719737908623 0.0 0.0 0.0 0.0 |
| Alternative pathway of fetal androgen synthesis 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Alzheimers disease 1.0 196.0 1.0414442700156985 0.6220079992876584 0.0 0.0 0.0 0.0 |
| Alzheimers disease and mirna effects 1.0 199.0 1.0253555967841683 0.6276501385631038 0.0 0.0 0.0 0.0 |
| Amino acid metabolism 1.0 71.0 2.9376093294460643 0.295480255529908 0.0 0.0 0.0 0.0 |
| Amino acid metabolism pathway excerpt histidine catabolism extension 1.0 3.0 10.0 0.01464105432669 0.0 0.0 0.0 0.0 |
| Ampactivated protein kinase ampk signaling 0.0 54.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Amplification and expansion of oncogenic pathways as metastatic traits 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Amyotrophic lateral sclerosis als 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Androgen receptor signaling pathway 0.0 80.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Angiogenesis 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Angiopoietinlike protein 8 regulatory pathway 1.0 107.0 1.932999614940316 0.410668613679594 0.0 0.0 0.0 0.0 |
| Angiotensin ii receptor type 1 pathway 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Antiviral and antiinflammatory effects of nrf2 on sarscov2 pathway 2.0 18.0 10.0 0.0034296220851759 0.0 0.0 0.0 0.0 |
| Apoe and mir146 in inflammation and atherosclerosis 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Apoptosis 1.0 65.0 3.214923469387755 0.2742474624411909 0.0 0.0 0.0 0.0 |
| Apoptosis modulation and signaling 0.0 65.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Apoptosis modulation by hsp70 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Apoptosisrelated network due to altered notch3 in ovarian cancer 2.0 42.0 10.0 0.0179094063189584 0.0 0.0 0.0 0.0 |
| Arachidonate epoxygenase epoxide hydrolase 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Arrhythmogenic right ventricular cardiomyopathy 1.0 45.0 4.6855287569573285 0.1988423464133734 0.0 0.0 0.0 0.0 |
| Aryl hydrocarbon receptor pathway wp2586 1.0 33.0 6.450255102040816 0.1499686155438198 0.0 0.0 0.0 0.0 |
| Aryl hydrocarbon receptor pathway wp2873 0.0 27.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Arylamine metabolism 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Aspirin and mirnas 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Atm signaling in development and disease 1.0 46.0 4.580952380952381 0.2027885470531376 0.0 0.0 0.0 0.0 |
| Atm signaling pathway 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Atr signaling 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Autophagy 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Autosomal recessive osteopetrosis pathways 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| B cell receptor signaling pathway 1.0 74.0 2.816046966731898 0.3058671484100957 0.0 0.0 0.0 0.0 |
| Base excision repair 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bdnftrkb signaling 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Benzene metabolism 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Benzoapyrene metabolism 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bile acids synthesis and enterohepatic circulation 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Biogenic amine synthesis 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Biomarkers for pyrimidine metabolism disorders 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Biomarkers for urea cycle disorders 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Biotin metabolism including iems 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bladder cancer 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Blood clotting cascade 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bmp signaling in eyelid development 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bmp2wnt4foxo1 pathway in primary endometrial stromal cell differentiation 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Bone morphogenic protein bmp signaling and regulation 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Brainderived neurotrophic factor bdnf signaling pathway 1.0 115.0 1.7959183673469388 0.433640456963297 0.0 0.0 0.0 0.0 |
| Breast cancer pathway 0.0 102.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Burn wound healing 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Calcium regulation in cardiac cells 0.0 80.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Caloric restriction and aging 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Camkk2 pathway 0.0 27.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cancer immunotherapy by ctla4 blockade 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cancer immunotherapy by pd1 blockade 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cannabinoid receptor signaling 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Canonical and noncanonical notch signaling 1.0 17.0 10.0 0.0802348466038066 0.0 0.0 0.0 0.0 |
| Canonical and noncanonical tgfb signaling 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Canonical nfkb pathway 1.0 8.0 10.0 0.0385773062479974 0.0 0.0 0.0 0.0 |
| Cardiac hypertrophic response 1.0 41.0 5.156122448979592 0.1828652209005429 0.0 0.0 0.0 0.0 |
| Cardiac progenitor differentiation 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ccl18 signaling pathway 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cell cycle 0.0 112.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cell differentiation expanded index 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cell differentiation index 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cell migration and invasion through p75ntr 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cells and molecules involved in local acute inflammatory response 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Celltype dependent selectivity of cck2r signaling 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cellular proteostasis 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cerebral organic acidurias including diseases 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Chemokine signaling pathway 1.0 92.0 2.2549899080511326 0.3651094145888684 0.0 0.0 0.0 0.0 |
| Cholesterol biosynthesis pathway 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cholesterol biosynthesis with skeletal dysplasias 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cholesterol metabolism with bloch and kandutschrussell pathways 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Chromosomal and microsatellite instability in colorectal cancer 0.0 65.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ciliary landscape 1.0 201.0 1.0148979591836735 0.631365625598012 0.0 0.0 0.0 0.0 |
| Ciliopathies 0.0 139.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Circadian rhythm genes 0.0 108.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Clear cell renal cell carcinoma pathways 0.0 68.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Codeine and morphine metabolism 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cohesin complex cornelia de lange syndrome 1.0 33.0 6.450255102040816 0.1499686155438198 0.0 0.0 0.0 0.0 |
| Common pathways underlying drug addiction 0.0 23.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Complement activation 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Complement and coagulation cascades 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Complement system 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Complement system in neuronal development and plasticity 0.0 52.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Congenital generalized lipodystrophy cgl 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Constitutive androstane receptor pathway 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Control of immune tolerance by vasoactive intestinal peptide 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Copper homeostasis 0.0 40.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cori cycle 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Corticotropinreleasing hormone signaling pathway 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Covid19 adverse outcome pathway 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cysteine and methionine catabolism 1.0 13.0 10.0 0.0619434524836269 0.0 0.0 0.0 0.0 |
| Cytokines and inflammatory response 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cytoplasmic ribosomal proteins 1.0 86.0 2.415606242496999 0.3459346535427879 0.0 0.0 0.0 0.0 |
| Cytosine methylation 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Cytosolic dnasensing pathway 1.0 44.0 4.794969150450879 0.1948770046367652 0.0 0.0 0.0 0.0 |
| Ddx1 as a regulatory component of the drosha microprocessor 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Degradation pathway of sphingolipids including diseases 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Deregulation of rab and rab effector genes in bladder cancer 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Development and heterogeneity of the ilc family 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Development of pulmonary dendritic cells and macrophage subsets 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Development of ureteric collection system 0.0 42.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Differentiation of white and brown adipocyte 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Disorders of folate metabolism and transport 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Disruption of postsynaptic signaling by cnv 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna damage response 0.0 64.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna damage response only atm dependent 1.0 87.0 2.387280493592786 0.3491693980885609 0.0 0.0 0.0 0.0 |
| Dna irdamage and cellular response via atr 0.0 77.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna irdouble strand breaks and cellular response via atm 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna mismatch repair 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna repair pathways full network 0.0 125.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dna replication 0.0 43.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dopamine metabolism 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dopaminergic neurogenesis 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Drug induction of bile acid pathway 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Dual hijack model of vif in hiv infection 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ebola virus infection in host 0.0 101.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ebsteinbarr virus lmp1 signaling 1.0 16.0 10.0 0.0756950383436983 0.0 0.0 0.0 0.0 |
| Ectoderm differentiation 0.0 95.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eda signaling in hair follicle development 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Effect of progerin on genes involved in hutchinsongilford progeria syndrome 2.0 25.0 10.0 0.0065792573185243 0.0 0.0 0.0 0.0 |
| Effects of nitric oxide 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Egfegfr signaling pathway 0.0 143.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Egfr tyrosine kinase inhibitor resistance 0.0 65.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eicosanoid metabolism via cyclooxygenases cox 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eicosanoid metabolism via cytochrome p450 monooxygenases pathway 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eicosanoid metabolism via lipooxygenases lox 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eicosanoid synthesis 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Electron transport chain oxphos system in mitochondria 0.0 91.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Embryonic stem cell pluripotency pathways 0.0 62.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Endochondral ossification 1.0 36.0 5.895626822157435 0.1624541869963563 0.0 0.0 0.0 0.0 |
| Endochondral ossification with skeletal dysplasias 1.0 36.0 5.895626822157435 0.1624541869963563 0.0 0.0 0.0 0.0 |
| Endoderm differentiation 0.0 109.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Endometrial cancer 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Endoplasmic reticulum stress response in coronavirus infection 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Endothelin pathways 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Energy metabolism 0.0 42.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Envelope proteins and their potential roles in edmd physiopathology 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Epithelial to mesenchymal transition in colorectal cancer 0.0 99.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Epo receptor signaling 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Erbb signaling pathway 0.0 71.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Erk pathway in huntingtons disease 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Estrogen metabolism 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Estrogen receptor pathway 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Estrogen signaling pathway 1.0 21.0 10.0 0.0981765691424607 0.0 0.0 0.0 0.0 |
| Ethanol effects on histone modifications 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ethanol metabolism production of ros by cyp2e1 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Eukaryotic transcription initiation 0.0 44.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ev release from cardiac cells and their functional effects 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Exerciseinduced circadian regulation 1.0 37.0 5.7312925170068025 0.1665759675679584 0.0 0.0 0.0 0.0 |
| Exrna mechanism of action and biogenesis 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Extracellular vesiclemediated signaling in recipient cells 0.0 22.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Extracellular vesicles in the crosstalk of cardiac cells 1.0 12.0 10.0 0.0573151884822011 0.0 0.0 0.0 0.0 |
| Factors and pathways affecting insulinlike growth factor igf1akt signaling 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial hyperlipidemia type 1 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial hyperlipidemia type 2 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial hyperlipidemia type 3 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial hyperlipidemia type 4 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial hyperlipidemia type 5 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Familial partial lipodystrophy fpld 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Farnesoid x receptor pathway 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fas ligand pathway and stress induction of heat shock proteins 1.0 39.0 5.428571428571429 0.1747599807978781 0.0 0.0 0.0 0.0 |
| Fatty acid betaoxidation 0.0 30.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fatty acid biosynthesis 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fatty acid omegaoxidation 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fatty acid transporters 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fbxl10 enhancement of maperk signaling in diffuse large bcell lymphoma 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ferroptosis 2.0 51.0 8.585884353741497 0.0257915242502586 0.0 0.0 0.0 0.0 |
| Fgf23 signaling in hypophosphatemic rickets and related disorders 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fgfr3 signaling in chondrocyte proliferation and terminal differentiation 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fibrin complement receptor 3 signaling pathway 1.0 23.0 9.391465677179962 0.1070183553885475 0.0 0.0 0.0 0.0 |
| Fluoroacetic acid toxicity 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fluoropyrimidine activity 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Focal adhesion 0.0 129.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Focal adhesion pi3kaktmtorsignaling pathway 1.0 167.0 1.226948610769609 0.5629626837931673 0.0 0.0 0.0 0.0 |
| Folate metabolism 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Folatealcohol and cancer pathway hypotheses 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Follicle stimulating hormone fsh signaling pathway 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Foxa2 pathway 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Foxp3 in covid19 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fragile x syndrome 0.0 96.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Fto obesity variant mechanism 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| G protein signaling pathways 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| G1 to s cell cycle control 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| G13 signaling pathway 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gaba metabolism aka ghb 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gaba receptor signaling 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Galanin receptor pathway 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gammaglutamyl cycle for the biosynthesis and degradation of glutathione including diseases 1.0 4.0 10.0 0.0194745623500658 0.0 0.0 0.0 0.0 |
| Ganglio sphingolipid metabolism 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gastric acid production 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gastric cancer network 1 0.0 23.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gastric cancer network 2 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gastrin signaling pathway 1.0 100.0 2.0711193568336426 0.3898210156701354 0.0 0.0 0.0 0.0 |
| Gdnfret signaling axis 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gene regulatory network modelling somitogenesis 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Genes associated with the development of rheumatoid arthritis 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Genes controlling nephrogenesis 0.0 27.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Genes related to primary cilium development based on crispr 0.0 93.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Genes targeted by mirnas in adipocytes 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glial cell differentiation 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glioblastoma signaling pathways 0.0 77.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glucocorticoid receptor pathway 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glucuronidation 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glutathione metabolism 1.0 10.0 10.0 0.0479914252810258 0.0 0.0 0.0 0.0 |
| Glycerolipids and glycerophospholipids 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glycerophospholipid biosynthetic pathway 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glycogen synthesis and degradation 1.0 33.0 6.450255102040816 0.1499686155438198 0.0 0.0 0.0 0.0 |
| Glycolysis and gluconeogenesis 0.0 35.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glycolysis in senescence 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glycosaminoglycan degradation 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Glycosylation and related congenital defects 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gpcrs class a rhodopsinlike 1.0 9.0 10.0 0.0432957136582515 0.0 0.0 0.0 0.0 |
| Gpcrs class b secretinlike 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gpcrs class c metabotropic glutamate pheromone 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gpcrs other 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gpr143 in melanocytes and retinal pigment epithelium cells 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Gpr40 pathway 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| H19 action rbe2f1 signaling and cdkbetacatenin activity 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hair follicle development cytodifferentiation part 3 of 3 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hair follicle development organogenesis part 2 of 3 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Head and neck squamous cell carcinoma 0.0 67.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Heart development 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hedgehog signaling pathway wp4249 0.0 32.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hedgehog signaling pathway wp47 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hematopoietic stem cell differentiation 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hematopoietic stem cell gene regulation by gabp alphabeta complex 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Heme biosynthesis 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hepatitis b infection 1.0 113.0 1.8283527696793005 0.4279811411777856 0.0 0.0 0.0 0.0 |
| Hepatitis c and hepatocellular carcinoma 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hepatocyte growth factor receptor signaling 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hereditary leiomyomatosis and renal cell carcinoma pathway 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hfe effect on hepcidin production 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hif1a and pparg regulation of glycolysis 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hijack of ubiquitination by sarscov2 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hippo signaling regulation pathways 0.0 73.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hippomerlin signaling dysregulation 0.0 81.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hippoyap signaling pathway 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Histone modifications 0.0 40.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Homologous recombination 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hostpathogen interaction of human coronaviruses apoptosis 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hostpathogen interaction of human coronaviruses autophagy 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hostpathogen interaction of human coronaviruses interferon induction 1.0 25.0 8.607142857142858 0.1157751708195439 0.0 0.0 0.0 0.0 |
| Hostpathogen interaction of human coronaviruses mapk signaling 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hypertrophy model 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hypothesized pathways in pathogenesis of cardiovascular disease 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Hypothetical craniofacial development pathway 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Id signaling pathway 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il1 and megakaryocytes in obesity 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il1 signaling pathway 1.0 48.0 4.385149804602692 0.2106238865633207 0.0 0.0 0.0 0.0 |
| Il10 antiinflammatory signaling pathway 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il17 signaling pathway 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il18 signaling pathway 2.0 167.0 2.520454545454545 0.1973052098349393 0.0 0.0 0.0 0.0 |
| Il2 signaling pathway 0.0 32.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il3 signaling pathway 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il4 signaling pathway 1.0 41.0 5.156122448979592 0.1828652209005429 0.0 0.0 0.0 0.0 |
| Il5 signaling pathway 0.0 32.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il6 signaling pathway 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il7 signaling pathway 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Il9 signaling pathway 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Imatinib and chronic myeloid leukemia 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Immune response to tuberculosis 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Inclusion body myositis 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Inflammatory response pathway 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Influence of laminopathies on wnt signaling 0.0 30.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Inhibition of exosome biogenesis and secretion by manumycin a in crpc cells 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Initiation of transcription and translation elongation at the hiv1 ltr 0.0 30.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Insulin signaling 1.0 136.0 1.513378684807256 0.4898475277533254 0.0 0.0 0.0 0.0 |
| Insulin signaling in adipocytes diabetic condition 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Insulin signaling in adipocytes normal condition 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Integrated cancer pathway 0.0 44.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Integrinmediated cell adhesion 0.0 73.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interactions between immune cells and micrornas in tumor microenvironment 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interactions between loxl4 and oxidative stress pathway 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interactions of natural killer cells in pancreatic cancer 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interactome of polycomb repressive complex 2 prc2 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interferon type i signaling pathways 0.0 44.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interleukin1 il1 structural pathway 1.0 43.0 4.909620991253644 0.1908924307699622 0.0 0.0 0.0 0.0 |
| Interleukin1 induced activation of nfkb 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Interleukin11 signaling pathway 1.0 37.0 5.7312925170068025 0.1665759675679584 0.0 0.0 0.0 0.0 |
| Intracellular trafficking proteins involved in cmt neuropathy 1.0 22.0 9.839650145772596 0.1026081339138497 0.0 0.0 0.0 0.0 |
| Intraflagellar transport proteins binding to dynein 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Irinotecan pathway 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Iron metabolism in placenta 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Joubert syndrome 0.0 67.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kallmann syndrome 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kennedy pathway from sphingolipids 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ketogenesis and ketolysis 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ketone bodies synthesis and degradation 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kininkallikrein pathway 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kisspeptinkisspeptin receptor system in the ovary 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kit receptor signaling pathway 0.0 48.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Krebs cycle disorders 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Kynurenine pathway and links to cell senescence 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ldlrad4 and what we know about it 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Leptin and adiponectin 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Leptin signaling pathway 2.0 68.0 6.363636363636363 0.0437266531990119 0.0 0.0 0.0 0.0 |
| Leptininsulin signaling overlap 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Let7 inhibition of es cell reprogramming 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Leukocyteintrinsic hippo pathway functions 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Linoleic acid metabolism affected by coronavirus infection 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Lipid metabolism pathway 0.0 25.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Lipid particles composition 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Liver x receptor pathway 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Lncrna in canonical wnt signaling and colorectal cancer 0.0 59.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Lncrnamediated mechanisms of therapeutic resistance 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ltf danger signal response pathway 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Lung fibrosis 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Major receptors targeted by epinephrine and norepinephrine 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Male infertility 0.0 72.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Malignant pleural mesothelioma 1.0 284.0 0.7112569409389198 0.7572979860277613 0.0 0.0 0.0 0.0 |
| Mammalian disorder of sexual development 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mammary gland development pathway embryonic development stage 1 of 4 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mammary gland development pathway involution stage 4 of 4 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mammary gland development pathway pregnancy and lactation stage 3 of 4 2.0 21.0 10.0 0.0046633751497463 0.0 0.0 0.0 0.0 |
| Mammary gland development pathway puberty stage 2 of 4 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Map3k1 role in promoting and blocking gonadal determination 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mapk and nfkb signaling pathways inhibited by yersinia yopj 1.0 11.0 10.0 0.0526645480715484 0.0 0.0 0.0 0.0 |
| Mapk cascade 0.0 30.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mapk pathway in congenital thyroid cancer 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mapk signaling pathway 3.0 151.0 4.31196089706728 0.0376182203289342 0.0 0.0 0.0 0.0 |
| Matrix metalloproteinases 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mbdnf and probdnf regulation of gaba neurotransmission 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Measles virus infection 1.0 87.0 2.387280493592786 0.3491693980885609 0.0 0.0 0.0 0.0 |
| Mechanoregulation and pathology of yaptaz via hippo and nonhippo mechanisms 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mecp2 and associated rett syndrome 1.0 51.0 4.120816326530612 0.2222355866483168 0.0 0.0 0.0 0.0 |
| Med and pseudoachondroplasia genes 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Melanoma 0.0 56.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Melatonin metabolism and effects 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mesodermal commitment pathway 0.0 105.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Met in type 1 papillary renal cell carcinoma 0.0 54.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metabolic pathway of ldl hdl and tg including diseases 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metabolic reprogramming in colon cancer 0.0 39.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metabolism of alphalinolenic acid 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metabolism of spingolipids in er and golgi apparatus 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metapathway biotransformation phase i and ii 0.0 60.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Metastatic brain tumor 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Methionine de novo and salvage pathway 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Methionine metabolism leading to sulfur amino acids and related disorders 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Methylation pathways 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mevalonate arm of cholesterol biosynthesis pathway 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mevalonate pathway 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mfap5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mfap5mediated ovarian cancer cell motility and invasiveness 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Microglia pathogen phagocytosis pathway 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Microrna for targeting cancer growth and vascularization in glioblastoma 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Microrna network associated with chronic lymphocytic leukemia 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Micrornas in cardiomyocyte hypertrophy 1.0 63.0 3.3192890059249507 0.2670314735990955 0.0 0.0 0.0 0.0 |
| Microtubule cytoskeleton regulation 0.0 42.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mir124 predicted interactions with cell cycle and differentiation 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mir222 in exerciseinduced cardiac growth 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mir5093p alteration of yap1ecm axis 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mir517 relationship with arcn1 and usp1 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirna biogenesis 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirna regulation of dna damage response 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirna regulation of p53 pathway in prostate cancer 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirna regulation of prostate cancer signaling pathways 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirna targets in ecm and membrane receptors 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirnas involved in dna damage response 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mirnas involvement in the immune response in sepsis 1.0 20.0 10.0 0.0937235599037543 0.0 0.0 0.0 0.0 |
| Mitochondrial complex i assembly model oxphos system 0.0 54.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial complex ii assembly 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial complex iii assembly 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial complex iv assembly 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial fatty acid synthesis pathway 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial gene expression 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial immune response to sarscov2 0.0 25.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mitochondrial long chain fatty acid betaoxidation 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Modulators of tcr signaling and t cell activation 1.0 39.0 5.428571428571429 0.1747599807978781 0.0 0.0 0.0 0.0 |
| Molybdenum cofactor moco biosynthesis 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Monoamine transport 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mrna processing 3.0 124.0 5.28837700017584 0.0227259758802294 0.0 0.0 0.0 0.0 |
| Mrna protein and metabolite inducation pathway by cyclosporin a 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Mthfr deficiency 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Myd88 distinct inputoutput pathway 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Myometrial relaxation and contraction pathways 0.0 89.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nad biosynthesis ii from tryptophan 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nad biosynthetic pathways 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nad metabolism 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nad metabolism in oncogeneinduced senescence and mitochondrial dysfunctionassociated senescence 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nad metabolism sirtuins and aging 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nanomaterial induced apoptosis 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nanomaterialinduced inflammasome activation 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nanoparticle triggered autophagic cell death 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nanoparticle triggered regulated necrosis 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nanoparticlemediated activation of receptor signaling 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ncrnas involved in stat3 signaling in hepatocellular carcinoma 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ncrnas involved in wnt signaling in hepatocellular carcinoma 0.0 49.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neovascularisation processes 0.0 25.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nephrogenesis 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nephrotic syndrome 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Netrinunc5b signaling pathway 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Network map of sarscov2 signaling pathway 0.0 96.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neural crest cell migration during development 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neural crest cell migration in cancer 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neural crest differentiation 0.0 60.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neurodegeneration with brain iron accumulation nbia subtypes pathway 0.0 40.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Neuroinflammation 1.0 10.0 10.0 0.0479914252810258 0.0 0.0 0.0 0.0 |
| Neuroinflammation and glutamatergic signaling 0.0 75.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nicotine effect on dopaminergic neurons 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nipbl role in dna damage cornelia de lange syndrome 1.0 9.0 10.0 0.0432957136582515 0.0 0.0 0.0 0.0 |
| Nitric oxide metabolism in cystic fibrosis 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nocgmppkg mediated neuroprotection 0.0 23.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nodlike receptor nlr signaling pathway 1.0 8.0 10.0 0.0385773062479974 0.0 0.0 0.0 0.0 |
| Nonalcoholic fatty liver disease 0.0 126.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nonclassical role of vitamin d 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nongenomic actions of 125 dihydroxyvitamin d3 0.0 50.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nonhomologous end joining 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nonsmall cell lung cancer 0.0 63.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Notch signaling 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Notch signaling pathway 0.0 49.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Notch1 regulation of endothelial cell calcification 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Novel intracellular components of rigilike receptor rlr pathway 1.0 47.0 4.48092280390417 0.2067156970649581 0.0 0.0 0.0 0.0 |
| Nrf2 pathway 1.0 70.0 2.980479148181012 0.2919842266274133 0.0 0.0 0.0 0.0 |
| Nrf2are regulation 2.0 21.0 10.0 0.0046633751497463 0.0 0.0 0.0 0.0 |
| Nrp1triggered signaling pathways in pancreatic cancer 0.0 38.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nsp1 from sarscov2 inhibits translation initiation in the host cell 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nuclear receptors 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nuclear receptors in lipid metabolism and toxicity 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nuclear receptors metapathway 1.0 164.0 1.2499060974082885 0.5563616870900763 0.0 0.0 0.0 0.0 |
| Nucleotide excision repair 0.0 48.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nucleotide excision repair in xeroderma pigmentosum 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nucleotide gpcrs 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nucleotide metabolism 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Nucleotidebinding oligomerization domain nod pathway 1.0 19.0 10.0 0.0892490045576324 0.0 0.0 0.0 0.0 |
| Oligodendrocyte specification and differentiation leading to myelin components for cns 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Omega3 omega6 fatty acid synthesis 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Omega9 fatty acid synthesis 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Oncostatin m signaling pathway 0.0 52.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Onecarbon metabolism 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Onecarbon metabolism and related pathways 2.0 36.0 10.0 0.0133509861907553 0.0 0.0 0.0 0.0 |
| Orexin receptor pathway 0.0 70.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Osteoblast differentiation and related diseases 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Osteoblast signaling 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Osteoclast signaling 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Osteopontin signaling 1.0 10.0 10.0 0.0479914252810258 0.0 0.0 0.0 0.0 |
| Osx and mirnas in tooth development 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ovarian infertility 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Overlap between signal transduction pathways contributing to lmna laminopathies 0.0 45.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Overview of interferonsmediated signaling pathway 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Overview of nanoparticle effects 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Overview of proinflammatory and profibrotic mediators 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Oxidation by cytochrome p450 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Oxidative damage response 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Oxidative phosphorylation 0.0 52.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Oxidative stress response 1.0 20.0 10.0 0.0937235599037543 0.0 0.0 0.0 0.0 |
| Oxysterols derived from cholesterol 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| P38 mapk signaling pathway 1.0 32.0 6.658986175115207 0.1457663642848915 0.0 0.0 0.0 0.0 |
| P53 transcriptional gene network 0.0 46.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pancreatic adenocarcinoma pathway 1.0 78.0 2.668698648290485 0.3194831905047319 0.0 0.0 0.0 0.0 |
| Parkinsons disease pathway 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Parkinubiquitin proteasomal system pathway 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pathogenesis of sarscov2 mediated by nsp9nsp10 complex 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pathogenic escherichia coli infection 0.0 45.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pathways affected in adenoid cystic carcinoma 0.0 55.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pathways of nucleic acid metabolism and innate immune sensing 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pdgf pathway 1.0 36.0 5.895626822157435 0.1624541869963563 0.0 0.0 0.0 0.0 |
| Pdgfrbeta pathway 0.0 26.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pentose phosphate metabolism 1.0 7.0 10.0 0.0338360956076009 0.0 0.0 0.0 0.0 |
| Pentose phosphate pathway in senescent cells 1.0 8.0 10.0 0.0385773062479974 0.0 0.0 0.0 0.0 |
| Peptide gpcrs 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Peroxiredoxin 2 induced ovarian failure 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Phase i biotransformations non p450 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Phosphodiesterases in neuronal function 0.0 22.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Phosphoinositides metabolism 0.0 41.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Photodynamic therapyinduced ap1 survival signaling 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Photodynamic therapyinduced hif1 survival signaling 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Photodynamic therapyinduced nfe2l2 nrf2 survival signaling 1.0 18.0 10.0 0.0847528009868792 0.0 0.0 0.0 0.0 |
| Photodynamic therapyinduced nfkb survival signaling 1.0 14.0 10.0 0.066549445548378 0.0 0.0 0.0 0.0 |
| Photodynamic therapyinduced unfolded protein response 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Physicochemical features and toxicityassociated pathways 0.0 53.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Physiological and pathological hypertrophy of the heart 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pi3kakt signaling pathway 2.0 175.0 2.401974951830443 0.2116527739749005 0.0 0.0 0.0 0.0 |
| Pi3kaktmtor signaling pathway and therapeutic opportunities 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pi3kaktmtor vitd3 signaling 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pilocytic astrocytoma 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pkcgamma calcium signaling pathway in ataxia 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Plateletmediated interactions with vascular and circulating cells 0.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pluripotent stem cell differentiation pathway 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ppar signaling pathway 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pparalpha pathway 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Praderwilli and angelman syndrome 0.0 29.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pregnane x receptor pathway 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Preimplantation embryo 0.0 27.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Primary focal segmental glomerulosclerosis fsgs 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Prion disease pathway 0.0 25.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Progeriaassociated lipodystrophy 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Prolactin signaling pathway 1.0 66.0 3.165149136577708 0.2778293030066073 0.0 0.0 0.0 0.0 |
| Prostaglandin and leukotriene metabolism in senescence 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Prostaglandin signaling 0.0 4.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Prostaglandin synthesis and regulation 0.0 22.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Proteasome degradation 0.0 51.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Proteoglycan biosynthesis 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Proximal tubule transport 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ptf1a related regulatory pathway 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Purine metabolism 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Purine metabolism and related disorders 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Purinergic signaling 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Pyrimidine metabolism 2.0 78.0 5.520833333333333 0.0559003563721154 0.0 0.0 0.0 0.0 |
| Pyrimidine metabolism and related diseases 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Quercetin and nfkb ap1 induced apoptosis 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Rac1pak1p38mmp2 pathway 1.0 56.0 3.7443413729128014 0.2412174988663298 0.0 0.0 0.0 0.0 |
| Rala downstream regulated genes 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ranklrank signaling pathway 1.0 45.0 4.6855287569573285 0.1988423464133734 0.0 0.0 0.0 0.0 |
| Ras and bradykinin pathways in covid19 0.0 10.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ras signaling 1.0 120.0 1.7196021265649115 0.4475497772550058 0.0 0.0 0.0 0.0 |
| Regucalcin in proximal tubule epithelial kidney cells 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Regulation of actin cytoskeleton 0.0 104.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Regulation of apoptosis by parathyroid hormonerelated protein 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Regulation of sister chromatid separation at the metaphaseanaphase transition 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Regulation of wnt bcatenin signaling by small molecule compounds 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Regulatory circuits of the stat3 signaling pathway 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Relationship between inflammation cox2 and egfr 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Reninangiotensinaldosterone system raas 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Resistin as a regulator of inflammation 1.0 25.0 8.607142857142858 0.1157751708195439 0.0 0.0 0.0 0.0 |
| Retinoblastoma gene in cancer 0.0 87.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Rett syndrome causing genes 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Riboflavin and coq disorders 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Robo4 and vegf signaling pathways crosstalk 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| S1p receptor signal transduction 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sars coronavirus and innate immunity 0.0 13.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 altering angiogenesis via nrp1 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 and ace2 receptor molecular mechanisms 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 and covid19 pathway 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 b117 variant antagonises innate immune activation 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 innate immunity evasion and cellspecific immune response 0.0 31.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sarscov2 replication organelle formation 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Scfa and skeletal muscle substrate metabolism 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Selective expression of chemokine receptors during tcell polarization 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Selenium micronutrient network 0.0 41.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serine metabolism 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin and anxiety 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin and anxietyrelated events 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin htr1 group and fos pathway 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin receptor 2 and elksrfgata4 signaling 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin receptor 467 and nr3c signaling 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Serotonin transporter activity 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Signal transduction through il1r 1.0 21.0 10.0 0.0981765691424607 0.0 0.0 0.0 0.0 |
| Sleep regulation 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Small cell lung cancer 1.0 80.0 2.6006199948333766 0.326192706464958 0.0 0.0 0.0 0.0 |
| Small ligand gpcrs 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Smc1smc3 role in dna damage cornelia de lange syndrome 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Somatic sex determination 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Somatroph axis gh and its relationship to dietary restriction and aging 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Somitogenesis in the context of spondylocostal dysostosis 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sphingolipid metabolism in senescence 0.0 23.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sphingolipid metabolism integrated pathway 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sphingolipid metabolism overview 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sphingolipid pathway 0.0 22.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Spinal cord injury 0.0 53.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Splicing factor nova regulated synaptic proteins 1.0 29.0 7.37463556851312 0.1330370821365251 0.0 0.0 0.0 0.0 |
| Srebf and mir33 in cholesterol and lipid homeostasis 0.0 12.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Srf and mirs in smooth muscle differentiation and proliferation 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Statin inhibition of cholesterol production 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Steroid biosynthesis 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sterol regulatory elementbinding proteins srebp signaling 0.0 65.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sting pathway in kawasakilike disease and covid19 1.0 13.0 10.0 0.0619434524836269 0.0 0.0 0.0 0.0 |
| Striated muscle contraction pathway 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sudden infant death syndrome sids susceptibility pathways 0.0 83.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sulfation biotransformation reaction 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Sulindac metabolic pathway 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Supression of hmgb1 mediated inflammation by thbd 1.0 7.0 10.0 0.0338360956076009 0.0 0.0 0.0 0.0 |
| Synaptic signaling pathways associated with autism spectrum disorder 0.0 37.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Synaptic vesicle pathway 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| T cell receptor and costimulatory signaling 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tamoxifen metabolism 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Target of rapamycin tor signaling 0.0 32.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tca cycle aka krebs or citric acid cycle 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tca cycle and deficiency of pyruvate dehydrogenase complex pdhc 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tca cycle in senescence 0.0 11.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tca cycle nutrient use and invasiveness of ovarian cancer 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tcell activation sarscov2 1.0 51.0 4.120816326530612 0.2222355866483168 0.0 0.0 0.0 0.0 |
| Tcell antigen receptor tcr pathway during staphylococcus aureus infection 1.0 37.0 5.7312925170068025 0.1665759675679584 0.0 0.0 0.0 0.0 |
| Tcell receptor tcr signaling pathway 1.0 56.0 3.7443413729128014 0.2412174988663298 0.0 0.0 0.0 0.0 |
| Tgfbeta receptor signaling 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tgfbeta receptor signaling in skeletal dysplasias 0.0 36.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tgfbeta signaling in thyroid cells for epithelialmesenchymal transition 0.0 14.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tgfbeta signaling pathway 0.0 117.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tgif disruption of shh signaling 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Thermogenesis 0.0 81.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Thiamine metabolic pathways 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Thymic stromal lymphopoietin tslp signaling pathway 0.0 33.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Thyroid hormones production and peripheral downstream signaling effects 0.0 58.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Thyroid stimulating hormone tsh signaling pathway 0.0 59.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tlr4 signaling and tolerance 1.0 21.0 10.0 0.0981765691424607 0.0 0.0 0.0 0.0 |
| Tnfalpha signaling pathway 1.0 78.0 2.668698648290485 0.3194831905047319 0.0 0.0 0.0 0.0 |
| Tnfrelated weak inducer of apoptosis tweak signaling pathway 1.0 33.0 6.450255102040816 0.1499686155438198 0.0 0.0 0.0 0.0 |
| Tolllike receptor signaling pathway 1.0 53.0 3.9615384615384617 0.2298835505782255 0.0 0.0 0.0 0.0 |
| Tolllike receptor signaling related to myd88 1.0 21.0 10.0 0.0981765691424607 0.0 0.0 0.0 0.0 |
| Tp53 network 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Transcription cofactors ski and skil protein partners 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Transcription factor regulation in adipogenesis 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Transcription factors regulate mirnas related to cardiac hypertrophy 0.0 7.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Transcriptional activation by nrf2 in response to phytochemicals 1.0 13.0 10.0 0.0619434524836269 0.0 0.0 0.0 0.0 |
| Transcriptional cascade regulating adipogenesis 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Translation factors 0.0 48.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Translation inhibitors in chronically activated pdgfra cells 0.0 44.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Transsulfuration and onecarbon metabolism 1.0 26.0 8.26204081632653 0.1201219647894398 0.0 0.0 0.0 0.0 |
| Transsulfuration pathway 0.0 9.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Triacylglyceride synthesis 0.0 16.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tryptophan catabolism leading to nad production 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tryptophan metabolism 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tumor suppressor activity of smarcb1 0.0 28.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type 2 papillary renal cell carcinoma 0.0 21.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type i collagen synthesis in the context of osteogenesis imperfecta 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type i interferon induction and signaling during sarscov2 infection 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type ii diabetes mellitus 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type ii interferon signaling ifng 0.0 15.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Type iii interferon signaling 0.0 5.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Tyrobp causal network in microglia 0.0 24.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Ultraconserved region 339 modulation of tumor suppressor micrornas in cancer 0.0 2.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Unfolded protein response 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Urea cycle and associated pathways 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Urea cycle and metabolism of amino groups 0.0 17.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Urea cycle and related diseases 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Valproic acid pathway 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vasopressinregulated water reabsorption 0.0 34.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vegfavegfr2 signaling pathway 4.0 355.0 2.426607209215905 0.0954360750806307 0.0 0.0 0.0 0.0 |
| Vitamin a and carotenoid metabolism 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin b12 disorders 0.0 8.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin b12 metabolism 0.0 22.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin b6dependent and responsive disorders 0.0 3.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin d in inflammatory diseases 1.0 20.0 10.0 0.0937235599037543 0.0 0.0 0.0 0.0 |
| Vitamin d metabolism 0.0 6.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin d receptor pathway 0.0 66.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Vitamin dsensitive calcium signaling in depression 1.0 19.0 10.0 0.0892490045576324 0.0 0.0 0.0 0.0 |
| White fat cell differentiation 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Wnt signaling 0.0 76.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Wnt signaling in kidney disease 0.0 18.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Wnt signaling pathway 0.0 44.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Wnt signaling pathway and pluripotency 1.0 74.0 2.816046966731898 0.3058671484100957 0.0 0.0 0.0 0.0 |
| Wntbetacatenin signaling pathway in leukemia 0.0 19.0 0.0 1.0 0.0 0.0 0.0 0.0 |
| Zinc homeostasis 0.0 20.0 0.0 1.0 0.0 0.0 0.0 0.0 |
|
|
